MCK241108P505000
- 0.04
- -3.16-98.75%
McKesson Newsroom
Mizuho Adjusts Price Target on McKesson to $550 From $530, Maintains Neutral Rating
McKesson Is Maintained at Outperform by Evercore ISI Group
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Evercore Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $680
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $535 to $688
McKesson Analyst Ratings
Barclays Remains a Buy on McKesson (MCK)
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
McKesson's Strong Q2 Performance and Upward EPS Guidance Justify Buy Rating
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Analysts Conflicted on These Healthcare Names: Medpace Holdings (MEDP), McKesson (MCK) and Glaukos (GKOS)
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Morgan Stanley Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $612
Morgan Stanley Keeps Their Buy Rating on McKesson (MCK)
TD Cowen Adjusts McKesson Price Target to $642 From $652
UBS Maintains McKesson(MCK.US) With Buy Rating, Cuts Target Price to $590
McKesson Is Maintained at Outperform by Leerink Partners
McKesson Analyst Ratings
Argus Research Maintains McKesson(MCK.US) With Buy Rating, Announces Target Price $570